Health
Super-backed company develops COVID treatment – Financial Standard
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by u…
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%.
The product, INNA-051, is being developed by Ena Respiratory, and works by stimulating and boosting the innate immune system. The study found that boosting the immune system this way limits the ability of the COVID-19 virus to infect the animals used in the study.
Ena Respiratory raised $11.7 million from a coalition of instit…
-
General18 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business18 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General20 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General21 hours agoAlbanese beats drum on economy as trade clouds gather